by Waylon Wright | Nov 30, 2016
The US FDA’s Emerging Technology program was established as a catalyst for new technologies to help modernize pharmaceutical development and manufacturing in areas where the FDA has limited review or inspection experience. Thomos O’Connor from the FDA’s Office of...
by Waylon Wright | Nov 22, 2016
Last Friday, the FDA halted the finalization of guidance that would have changed the way lab-developed tests (LDTs) are regulated. The reason? The presidential election. The current administration now enters its waning hours and the FDA decided to suspend guidance...
by Waylon Wright | Nov 17, 2016
“Just Google it” has shifted from a colloquialism spoken within small circles to an expression used ubiquitously around the world, so much so that Google, Inc. pleaded the public ten years ago to only use their name when referring to the company to avoid losing its...
by Waylon Wright | Nov 17, 2016
Pearl Pathways is excited to announce the hiring of Phillip Bishop as a quality analyst. Bishop will help the Pearl team serve medical device and biopharmaceutical companies. Bishop brings 13 years of quality control (QC) laboratory experience to the Pearl Pathways...
by Waylon Wright | Nov 15, 2016
As we enter the holiday season, please keep in mind of our operating hours. Pearl IRB will not hold a full board meeting on November 23rd but meetings will resume as scheduled the following week. The office will be open during normal business hours (8 AM – 5 PM EST)...
